180 related articles for article (PubMed ID: 19734846)
1. Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes.
Rozeman LB; de Bruijn IH; Bacchini P; Staals EL; Bertoni F; Bovée JV; Hogendoorn PC
Mod Pathol; 2009 Nov; 22(11):1489-98. PubMed ID: 19734846
[TBL] [Abstract][Full Text] [Related]
2. Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma.
Bovée JV; van den Broek LJ; Cleton-Jansen AM; Hogendoorn PC
Lab Invest; 2000 Dec; 80(12):1925-34. PubMed ID: 11140704
[TBL] [Abstract][Full Text] [Related]
3. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
4. PTHrP and Bcl-2: essential regulatory molecules in chondrocyte differentiation and chondrogenic tumors.
Amling M; Pösl M; Hentz MW; Priemel M; Delling G
Verh Dtsch Ges Pathol; 1998; 82():160-9. PubMed ID: 10095428
[TBL] [Abstract][Full Text] [Related]
5. The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting.
Hameetman L; Kok P; Eilers PH; Cleton-Jansen AM; Hogendoorn PC; Bovée JV
Virchows Arch; 2005 Apr; 446(4):430-7. PubMed ID: 15744499
[TBL] [Abstract][Full Text] [Related]
6. Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma.
Sakamoto A; Oda Y; Iwamoto Y; Tsuneyoshi M
J Cancer Res Clin Oncol; 1999 Oct; 125(10):541-8. PubMed ID: 10473866
[TBL] [Abstract][Full Text] [Related]
7. Dedifferentiated chondrosarcomas arising in preexisting osteochondromas.
Staals EL; Bacchini P; Mercuri M; Bertoni F
J Bone Joint Surg Am; 2007 May; 89(5):987-93. PubMed ID: 17473135
[TBL] [Abstract][Full Text] [Related]
8. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features.
Makise N; Sekimizu M; Konishi E; Motoi T; Kubo T; Ikoma H; Watanabe SI; Okuma T; Hiraoka N; Fukayama M; Kawai A; Ichikawa H; Yoshida A
Mod Pathol; 2019 Mar; 32(3):435-445. PubMed ID: 30291346
[TBL] [Abstract][Full Text] [Related]
9. Matrix biochemistry and cell biology of dedifferentiated chondrosarcomas.
Dornauer K; Söder S; Inwards CY; Bovee JV; Aigner T
Pathol Int; 2010 May; 60(5):365-72. PubMed ID: 20518886
[TBL] [Abstract][Full Text] [Related]
10. Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance.
Boehme KA; Schleicher SB; Traub F; Rolauffs B
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29361725
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
12. Dedifferentiated peripheral chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of four cases.
Franchi A; Baroni G; Sardi I; Giunti L; Capanna R; Campanacci D
Virchows Arch; 2012 Mar; 460(3):335-42. PubMed ID: 22350005
[TBL] [Abstract][Full Text] [Related]
13. Dedifferentiated chondrosarcoma with rhabdomyosarcomatous differentiation.
Reith JD; Bauer TW; Fischler DF; Joyce MJ; Marks KE
Am J Surg Pathol; 1996 Mar; 20(3):293-8. PubMed ID: 8772782
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of human chondrosarcomas for matrix production and cancer markers.
Söderström M; Böhling T; Ekfors T; Nelimarkka L; Aro HT; Vuorio E
Int J Cancer; 2002 Jul; 100(2):144-51. PubMed ID: 12115562
[TBL] [Abstract][Full Text] [Related]
15. [Pathomorphology of malignant chondrogenic bone tumors--an analysis of 94 cases from the Hamburg Bone Tumor Register (1974-1989)].
Delling G; Welkerling H
Z Orthop Ihre Grenzgeb; 1992; 130(1):1-8. PubMed ID: 1532267
[TBL] [Abstract][Full Text] [Related]
16. Rb-loss is associated with high malignancy in chondrosarcoma.
Röpke M; Boltze C; Meyer B; Neumann HW; Roessner A; Schneider-Stock R
Oncol Rep; 2006 Jan; 15(1):89-95. PubMed ID: 16328039
[TBL] [Abstract][Full Text] [Related]
17. Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling.
Hameetman L; Rozeman LB; Lombaerts M; Oosting J; Taminiau AH; Cleton-Jansen AM; Bovée JV; Hogendoorn PC
J Pathol; 2006 Aug; 209(4):501-11. PubMed ID: 16755518
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of matrilin-3 not only in osteoarthritic articular cartilage but also in cartilage-forming tumors, and down-regulation of SOX9 via epidermal growth factor domain 1-dependent signaling.
Vincourt JB; Vignaud JM; Lionneton F; Sirveaux F; Kawaki H; Marchal S; Lomazzi S; Plénat F; Guillemin F; Netter P; Takigawa M; Mainard D; Magdalou J
Arthritis Rheum; 2008 Sep; 58(9):2798-808. PubMed ID: 18759284
[TBL] [Abstract][Full Text] [Related]
19. p53 expression in dedifferentiated chondrosarcoma.
Simms WW; Ordóñez NG; Johnston D; Ayala AG; Czerniak B
Cancer; 1995 Jul; 76(2):223-7. PubMed ID: 8625095
[TBL] [Abstract][Full Text] [Related]
20. Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
van Oosterwijk JG; Meijer D; van Ruler MA; van den Akker BE; Oosting J; Krenács T; Picci P; Flanagan AM; Liegl-Atzwanger B; Leithner A; Athanasou N; Daugaard S; Hogendoorn PC; Bovée JV
Am J Pathol; 2013 Apr; 182(4):1347-56. PubMed ID: 23415961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
